Editing Coronary artery disease (section)

===Medications===
* [[Statin]]s, which reduce cholesterol, reduce the risk of coronary artery disease<ref>{{cite journal | vauthors = Gutierrez J, Ramirez G, Rundek T, Sacco RL | title = Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis | journal = Archives of Internal Medicine | volume = 172 | issue = 12 | pages = 909–19 | date = June 2012 | pmid = 22732744 | doi = 10.1001/archinternmed.2012.2145 | doi-access = free }}<!--|access-date=26 October 2015--></ref>
* [[Medical use of nitroglycerin|Nitroglycerin]]<ref name="medline">{{MedlinePlusEncyclopedia|a601086|Nitroglycerin Sublingual}}</ref>
* Calcium channel blockers and/or beta-blockers<ref name="Ohman2016">{{cite journal | vauthors = Ohman EM | title = Clinical Practice: Chronic Stable Angina | journal = The New England Journal of Medicine | volume = 374 | issue = 12 | pages = 1167–76 | date = March 2016 | pmid = 27007960 | doi = 10.1056/NEJMcp1502240 }}</ref>
* [[Antiplatelet drug]]s such as [[aspirin]]<ref name="Ohman2016"/><ref name="Grove2015">{{cite journal | vauthors = Grove EL, Würtz M, Thomas MR, Kristensen SD | title = Antiplatelet therapy in acute coronary syndromes | journal = Expert Opinion on Pharmacotherapy | volume = 16 | issue = 14 | pages = 2133–47 | date = 2015 | pmid = 26293612 | doi = 10.1517/14656566.2015.1079619 | type = Review | s2cid = 9841653 }}</ref>

It is recommended that blood pressure typically be reduced to less than 140/90 mmHg.<ref name=Ros2015/> The diastolic blood pressure should not be below 60 mmHg. Beta-blockers are recommended first line for this use.<ref name="Ros2015">{{cite journal | vauthors = Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Findeiss L, Gersh BJ, Gore JM, Levy D, Long JB, O'Connor CM, O'Gara PT, Ogedegbe G, Oparil S, White WB | display-authors = 6 | title = Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension | journal = Circulation | volume = 131 | issue = 19 | pages = e435–70 | date = May 2015 | pmid = 25829340 | doi = 10.1161/cir.0000000000000207 | pmc = 8365343 | doi-access = free }}<!--|access-date=26 October 2015--></ref>

====Aspirin====
In those with no previous history of heart disease, aspirin decreases the risk of a myocardial infarction but does not change the overall risk of death.<ref>{{cite journal | vauthors = Guirguis-Blake JM, Evans CV, Senger CA, O'Connor EA, Whitlock EP | title = Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force | journal = Annals of Internal Medicine | volume = 164 | issue = 12 | pages = 804–13 | date = June 2016 | pmid = 27064410 | doi = 10.7326/M15-2113 | type = Systematic Review and Meta-Analysis | doi-access = free }}</ref> Aspirin therapy to prevent heart disease is thus recommended only in adults who are at increased risk for cardiovascular events, which may include [[postmenopausal]]  females, males above 40, and younger people with risk factors for coronary heart disease, including [[high blood pressure]], a family history of heart disease, or [[diabetes]]. The benefits outweigh the harms most favorably in people at high risk for a cardiovascular event, where high risk is defined as at least a 3% chance over five years, but others with lower risk may still find the potential benefits worth the associated risks.<ref name="pmid11790071">{{cite journal | author = U.S. Preventive Services Task Force | title = Aspirin for the primary prevention of cardiovascular events: recommendation and rationale | journal = Annals of Internal Medicine | volume = 136 | issue = 2 | pages = 157–60 | date = January 2002 | pmid = 11790071 | doi = 10.7326/0003-4819-136-2-200201150-00015 | doi-access = free }}</ref>

====Anti-platelet therapy====
[[Clopidogrel]] plus aspirin (dual anti-platelet therapy) reduces cardiovascular events more than aspirin alone in those with a [[STEMI]]. In others at high risk but not having an acute event, the evidence is weak.<ref>{{cite journal | vauthors = Squizzato A, Bellesini M, Takeda A, Middeldorp S, Donadini MP | title = Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events | journal = The Cochrane Database of Systematic Reviews | volume = 2017 | pages = CD005158 | date = December 2017 | issue = 12 | pmid = 29240976 | pmc = 6486024 | doi = 10.1002/14651858.CD005158.pub4 }}</ref> Specifically, its use does not change the risk of death in this group.<ref>{{cite web|title=FDA Drug Safety Communication: FDA review finds long-term treatment with blood-thinning medicine Plavix (clopidogrel) does not change risk of death|url=https://www.fda.gov/Drugs/DrugSafety/ucm471286.htm|website=FDA|access-date=25 January 2016|date=6 November 2015|url-status=live|archive-url=https://web.archive.org/web/20160204011823/https://www.fda.gov/Drugs/DrugSafety/ucm471286.htm|archive-date=4 February 2016}}</ref> In those who have had a stent, more than 12 months of clopidogrel plus aspirin does not affect the risk of death.<ref>{{cite journal | vauthors = Elmariah S, Mauri L, Doros G, Galper BZ, O'Neill KE, Steg PG, Kereiakes DJ, Yeh RW | display-authors = 6 | title = Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis | journal = Lancet | volume = 385 | issue = 9970 | pages = 792–98 | date = February 2015 | pmid = 25467565 | pmc = 4386690 | doi = 10.1016/S0140-6736(14)62052-3 }}<!--|access-date=26 October 2015--></ref>